Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

The recent presentation of the long-term results of the JCOG0802 phase 3 trial has sparked discussion within the international thoracic surgical community. Initial 5-year results in 2022 reported a ...

In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...

The trial showed fenebrutinib reduced disability progression risk by 12% compared to Ocrevus, the only approved PPMS ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...

A new trial from China published in the BMJ journal revealed that telesurgery was non-inferior to standard local robotic ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

AI mammography detects breast cancers with 6.7% more accuracy and reduces missed cancers by 12%, making breast screening ...

Detailed price information for Thiogenesis Therapeutics Corp (TTI-X) from The Globe and Mail including charting and trades.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Objective: To investigate whether continuous positive airway pressure during spontaneous breathing trial is non-inferior to pressure support by comparing both techniques in mechanically ventilated ...